Biomunex Inc. to focus on R&D and business development activities in
the US
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biomunex Pharmaceuticals, a biopharmaceutical company focused on
providing immuno-therapeutics through the discovery and development of
bi- and multi-specific antibodies, today announces that it has
established its US subsidiary, Biomunex Pharmaceuticals Inc., in
Cambridge, Massachusetts, USA.
The opening of this subsidiary is a first step in the company’s strategy
to expand Biomunex’ activities in the US, with initial focus on
facilitating Research & Development partnerships and business
development activities with pharmaceutical companies and leading
academic institutions.
Emphasizing Biomunex’ US presence, company executives will be presenting
at several US-based events in the upcoming months:
-
Dr. Pierre-Emmanuel Gerard, CEO of Biomunex, is presenting at the 8th
International Cancer Cluster (June 3rd), and also
attending biopartnering sessions at BIO
2019 (June 3-6, Philadelphia, PA) -
Dr. Eugene Zhukovsky, CSO of Biomunex Pharmaceuticals SAS, is
presenting the BiXAb® platform and the company’s pipeline
at the Next
Generation Protein Therapeutics & Bioconjugates Summit (June
18-20, San Francisco, CA) and 10th
Annual Summit World Bispecific (September 17-19, Waltham, MA)
“Following our recent licensing agreement with Sanofi for the generation
and optimization of bi- and multi-specific antibody therapeutics, we are
excited about ramping up our R&D and partnering activities in the United
States with the establishment of Biomunex Inc.,” said Dr. Gerard. “We
are delighted to open our US subsidiary in Cambridge, MA, which probably
represents the largest biotech cluster in the world, especially in the
therapeutic antibody field. Biomunex’ ambition is to develop its product
pipeline globally and this first step paves the way for US developments.”
“The establishment of the US subsidiary will contribute to our global
R&D objectives by increasing discovery and development partnerships
based on the BiXAb® technology with major US academic and
industrial teams. Biomunex Inc. will also accelerate the preclinical and
clinical development of our proprietary BiXAb® antibodies,”
added Dr. Zhukovsky.
About the BiXAb® platform
Biomunex’
Plug-and-Play BiXAb® platform generates next-generation bi-
and multi-specific antibodies. This technology enables the turnkey
formatting of a BiXAb® antibody from any pair of monospecific
monoclonal antibodies as building blocks, in a timely and cost-effective
manner. The BiXAb® platform possesses all key properties
expected of an ideal bispecific antibody technology: fast design and
modularity, excellent drug-like properties and manufacturability,
multi-specific capability, versatility. The BiXAb® platform
enables Biomunex to develop immuno-oncology drug candidates with high
anti-tumor activity demonstrating synergy on targets. Biomunex also
develops this platform for new disruptive technologies based on
multi-specific antibodies and T-cell redirection.
About Biomunex
Biomunex is a biopharmaceutical company
providing innovative immuno-therapeutics through the discovery and
development of bi- and multi-specific antibodies. Its pipeline includes
bispecific antibodies in early development and disruptive discovery
programs for immuno-oncology that will soon enable the company to reach
clinical stage. After an out-licensing agreement with Sanofi, Biomunex
continues to leverage its technology to partner with international
pharmaceutical and biotechnology companies.
www.biomunex.com
Contacts
Media contact: Agnes Stephens, agnes@ala.com,
+44 1273 675 100